gerd
(2)
Phathom Pharmaceuticals
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company built around vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB) it licensed from Takeda in 2019 for the U.S., Europe and Canada. Its lead product, VOQUEZNA, won FDA approval in late 2023 - the first major innovation in U.S. GERD treatment in over 30 years - and is sold for non-erosive and erosive GERD plus H. pylori infection via its DUAL PAK and TRIPLE PAK regimens. The company reached $175.1 million in net revenue in 2025 and expects operating profitability in 2026.
Oshi Health
Oshi Health is a virtual-first gastrointestinal care clinic that gives the roughly one in four Americans living with digestive disorders fast access to a coordinated team of GI providers, registered dietitians, behavioral health specialists, and care coordinators. Available in all 50 states as an in-network benefit, Oshi pairs unlimited virtual visits and messaging with evidence-based, whole-person treatment - an approach a national health plan's analysis tied to 92% symptom improvement, 98% patient satisfaction, and more than $10,000 in medical cost savings per patient over six months.